Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1995 1
1998 1
2000 2
2006 3
2007 1
2010 3
2011 4
2012 3
2013 1
2015 6
2016 5
2017 1
2018 4
2019 7
2020 2
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Cell killing by antibody-drug conjugates.
Kovtun YV, Goldmacher VS. Kovtun YV, et al. Cancer Lett. 2007 Oct 8;255(2):232-40. doi: 10.1016/j.canlet.2007.04.010. Epub 2007 Jun 5. Cancer Lett. 2007. PMID: 17553616 Review.
3,5-Bis(acetaldehyde) substituted BODIPY.
Shandura MP, Yakubovskyi VP, Kovtun YP. Shandura MP, et al. Among authors: kovtun yp. Org Biomol Chem. 2013 Feb 7;11(5):835-41. doi: 10.1039/c2ob27004h. Epub 2012 Dec 12. Org Biomol Chem. 2013. PMID: 23235924
Peptide-Cleavable Self-immolative Maytansinoid Antibody-Drug Conjugates Designed To Provide Improved Bystander Killing.
Costoplus JA, Veale KH, Qiu Q, Ponte JF, Lanieri L, Setiady Y, Dong L, Skaletskaya A, Bartle LM, Salomon P, Wu R, Maloney EK, Kovtun YV, Ab O, Lai K, Chari RVJ, Widdison WC. Costoplus JA, et al. Among authors: kovtun yv. ACS Med Chem Lett. 2019 Sep 27;10(10):1393-1399. doi: 10.1021/acsmedchemlett.9b00310. eCollection 2019 Oct 10. ACS Med Chem Lett. 2019. PMID: 31620224 Free PMC article.
Antibody-maytansinoid conjugates designed to bypass multidrug resistance.
Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, Lai KC, Widdison WC, Kellogg B, Johnson H, Pinkas J, Lutz RJ, Singh R, Goldmacher VS, Chari RV. Kovtun YV, et al. Cancer Res. 2010 Mar 15;70(6):2528-37. doi: 10.1158/0008-5472.CAN-09-3546. Epub 2010 Mar 2. Cancer Res. 2010. PMID: 20197459
A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity.
Miller ML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, Archer KE, Maloney EK, Audette CA, Mayo MF, Wilhelm A, Modafferi HA, Singh R, Pinkas J, Goldmacher V, Lambert JM, Chari RV. Miller ML, et al. Among authors: kovtun y. Mol Cancer Ther. 2016 Aug;15(8):1870-8. doi: 10.1158/1535-7163.MCT-16-0184. Epub 2016 May 23. Mol Cancer Ther. 2016. PMID: 27216304
A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs).
Miller ML, Shizuka M, Wilhelm A, Salomon P, Reid EE, Lanieri L, Sikka S, Maloney EK, Harvey L, Qiu Q, Archer KE, Bai C, Vitharana D, Harris L, Singh R, Ponte JF, Yoder NC, Kovtun Y, Lai KC, Ab O, Pinkas J, Keating TA, Chari RVJ. Miller ML, et al. Among authors: kovtun y. Mol Cancer Ther. 2018 Mar;17(3):650-660. doi: 10.1158/1535-7163.MCT-17-0940. Epub 2018 Feb 13. Mol Cancer Ther. 2018. PMID: 29440292
42 results